



Supplementary Fig. S2. Effects of anti-drug antibodies on plasma ozoralizumab concentration and ACR20 response. *ACR20* $\geq$ 20% improvement according to the American College of Rheumatology criteria, *BL* baseline, *SD* standard deviation, *TB* treatment-boasted, *TI* treatment-induced.

OHZORA trial



NATSUZORA trial

